N
Nykode Therapeutics ASA
OSE:NYKD
Nykode Therapeutics ASA
OSE:NYKD
Price:
3.084
NOK
3.14%
Market Closed
Market Cap:
kr1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
NO |
|
SG Holdings Co Ltd
TSE:9143
|
JP |
|
Bidvest Group Ltd
OTC:BDVSY
|
ZA |
|
A
|
Agillic A/S
CSE:AGILC
|
DK |
|
K
|
Koolearn Technology Holding Ltd
HKEX:1797
|
CN |
|
A
|
Arctic Minerals AB (publ)
STO:ARCT
|
SE |
|
H
|
Huaxi Holdings Company Ltd
HKEX:1689
|
HK |
|
S
|
Safeplus International Holdings Ltd
OTC:ACAI
|
US |
|
K
|
Kokusai Chart Corp
TSE:3956
|
JP |
|
FormPipe Software AB
STO:FPIP
|
SE |
|
S
|
SeAH Holdings Corp
KRX:058650
|
KR |
|
C
|
Corporacion Interamericana de Entretenimiento SAB de CV
BMV:CIEB
|
MX |
|
Hubei Feilihua Quartz Glass Co Ltd
SZSE:300395
|
CN |
Balance Sheet
Balance Sheet Decomposition
Nykode Therapeutics ASA
Nykode Therapeutics ASA
Balance Sheet Decomposition is not available for
Nykode Therapeutics ASA
Nykode Therapeutics ASA
Balance Sheet
Nykode Therapeutics ASA
Nykode Therapeutics ASA
Currency: USD
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
2
|
4
|
3
|
10
|
183
|
216
|
206
|
162
|
115
|
60
|
|
| Cash |
0
|
4
|
3
|
10
|
183
|
216
|
206
|
162
|
0
|
0
|
|
| Cash Equivalents |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
115
|
60
|
|
| Short-Term Investments |
0
|
16
|
11
|
22
|
25
|
12
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
22
|
1
|
1
|
1
|
20
|
26
|
4
|
1
|
1
|
2
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
19
|
24
|
3
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
1
|
0
|
1
|
1
|
2
|
2
|
1
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
1
|
2
|
2
|
3
|
1
|
0
|
|
| Total Current Assets |
25
|
21
|
15
|
33
|
229
|
256
|
212
|
166
|
117
|
62
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
9
|
10
|
11
|
8
|
6
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
9
|
10
|
11
|
8
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
1
|
3
|
5
|
7
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
32
|
29
|
32
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
25
N/A
|
21
-15%
|
15
-29%
|
33
+120%
|
230
+589%
|
266
+15%
|
221
-17%
|
208
-6%
|
153
-26%
|
100
-35%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
1
|
1
|
2
|
2
|
3
|
2
|
1
|
1
|
4
|
|
| Accrued Liabilities |
0
|
0
|
0
|
1
|
6
|
4
|
8
|
6
|
3
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Other Current Liabilities |
1
|
0
|
1
|
2
|
5
|
23
|
28
|
12
|
4
|
1
|
|
| Total Current Liabilities |
2
|
1
|
1
|
4
|
13
|
31
|
39
|
21
|
9
|
6
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
6
|
4
|
4
|
2
|
1
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
31
|
29
|
21
|
12
|
5
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
1
|
7
|
5
|
0
|
0
|
1
|
1
|
|
| Total Liabilities |
2
N/A
|
1
-38%
|
1
+21%
|
6
+339%
|
51
+789%
|
72
+40%
|
64
-10%
|
37
-43%
|
17
-53%
|
8
-51%
|
|
| Equity | |||||||||||
| Common Stock |
21
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
5
|
9
|
15
|
31
|
121
|
115
|
76
|
45
|
10
|
3
|
|
| Additional Paid In Capital |
8
|
28
|
28
|
59
|
60
|
82
|
83
|
129
|
129
|
97
|
|
| Other Equity |
0
|
0
|
0
|
1
|
3
|
3
|
3
|
3
|
3
|
3
|
|
| Total Equity |
23
N/A
|
20
-13%
|
14
-31%
|
28
+99%
|
179
+547%
|
194
+9%
|
157
-19%
|
171
+9%
|
136
-20%
|
92
-33%
|
|
| Total Liabilities & Equity |
25
N/A
|
21
-15%
|
15
-29%
|
33
+120%
|
230
+589%
|
266
+15%
|
221
-17%
|
208
-6%
|
153
-26%
|
100
-35%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
56
|
56
|
56
|
55
|
285
|
290
|
295
|
327
|
327
|
327
|
|
Switch to:
Switch to:
See Also
Discover More
